Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer-Reference-Cited by-同舟云学术

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Published:2018-01-24 Issue:4 Volume:8 Page:444-457
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Annala Matti,Vandekerkhove Gillian,Khalaf Daniel,Taavitsainen Sinja,Beja Kevin,Warner Evan W.,Sunderland Katherine,Kollmannsberger Christian,Eigl Bernhard J.,Finch Daygen,Oja Conrad D.,Vergidis Joanna,Zulfiqar Muhammad,Azad Arun A.,Nykter Matti,Gleave Martin E.,Wyatt Alexander W.,Chi Kim N.

Funder

Canadian Cancer Society Research Institute (CCSRI)

Prostate Cancer Canada (PCC)

Prostate Cancer Foundation (PCF)

Terry Fox Research Institute (TFRI)

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 403 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer;Drug Resistance Updates;2024-11

3. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

4. Machine learning based androgen receptor regulatory gene-related random forest survival model for precise treatment decision in prostate cancer;Heliyon;2024-09

5. Evaluation of the prognostic role of TP53 gene mutations in prostate cancer outcome: A systematic review and meta-analysis;Clinical Genitourinary Cancer;2024-09